Meeting
2022 ASCO Annual Meeting
Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.
Authors
Russell J. Schilder
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Russell J. Schilder , John D. Powderly , Haeseong Park , Mehmet Asim Bilen , Meredith McKean , Rena May , Hui Feng , Sheng Yao , Patricia Keegan , Aung Naing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT04137900
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2643)
DOI
10.1200/JCO.2022.40.16_suppl.2643
Abstract #
2643
Poster Bd #
297
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study.
First Author: Nong Xu
Poster
2022 ASCO Annual Meeting
Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.
First Author: Jun Ma
Poster
2021 ASCO Annual Meeting
Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
First Author: Cai Zhou
Poster
2021 ASCO Annual Meeting
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
First Author: Stéphane Champiat